Ophthalmology Therapeutics Sector Gains Momentum with Surge of Corporate Activities and New Product Launches

　　【Pharmaceutical Network Industry Dynamics】With the aggravation of population aging, the increase in the number of people with myopia, and the significant improvement in national health awareness, eye health management has become an important part of the "Healthy China 2030" strategy. Benefiting from this, the ophthalmic medical market scale has begun to show a steady growth trend, while more and more enterprises are also accelerating their layout in this field.
 

Not long ago, Carl Zeiss Shanghai Co., Ltd. launched its new product, the "ZEISS ARTEVO 800 Ophthalmic Navigation Surgery System."Microscope"(hereinafter referred to as "Carl Zeiss ARTEVO 800") was officially launched at this year's CIIE."
 

According to reports, the Carl Zeiss ARTEVO 800 is an ophthalmic navigation surgical microscope that integrates digital optics. It has now received approval from the China National Medical Products Administration for market release. This device can significantly enhance the image resolution in the surgical field and features color management and software-based image post-processing technology, allowing surgeons to break free from the constraints of traditional eyepiece observation and perform surgeries with high-definition image quality.Surgical OperationOperation. At the same time, the Carl Zeiss ARTEVO 800 also has a relatively excellent depth of field, allowing surgeons to perform surgical operations under high-resolution and highly restored image quality. Especially during micrometer-level macular surgery, it provides surgeons with more operating space.
 

On the afternoon of November 6, Carl Zeiss successfully held a cooperation signing ceremony with Bright Eye Hospital Group Co., Ltd. at the CIIE. The two parties reached a cooperation on five Carl Zeiss ARTEVO 800 ophthalmic navigation surgical microscopes.
 

Alcon also brought 38 innovative achievements to this CIIE, including 14 innovative products. Notably, in the dry eye product series, in addition to artificial tears, a physical therapy device – the Systane iLux® MGD Treatment System – was also showcased. The Systane iLux® MGD Treatment System, similar to the exhibited products from Johnson & Johnson and Lumenis, is a physical therapy treatment for meibomian gland dysfunction.
 

In addition, at this CIIE, Aier Eye Hospital Group announced new strategic partnerships with several international medical brands such as Alcon, Carl Zeiss, and Johnson & Johnson Vision, signing cooperation framework agreements with the partners. Among them, Aier Eye Hospital Group completed the signing with Johnson & Johnson Vision to jointly promote the introduction and marketing of new ophthalmic technologies and products in the Chinese market. The world's first extended depth-of-field intraocular lens providing 33cm near vision — TECNIS Synergy™, a new generation EDOF intraocular lens, will be the first to carry out "pilot trials" at Boao Aier Eye Hospital.
 

In addition to showcasing new products and announcing new collaborations, an ophthalmology company has recently "entered" the track of listed ophthalmology companies. On November 7, on its first day of going public, Huaxia Ophthalmology's stock price surged over 30% at noon. As a private medical chain group specializing in ophthalmic services, Huaxia Ophthalmology provides domestic and international patients with diagnosis and treatment for various ophthalmic diseases. It has established a comprehensive ophthalmic service system covering eight major sub-specialties including cataract, refractive error, retina, strabismus & pediatric ophthalmology, cornea and ocular surface, glaucoma, orbital and ocular tumors, ocular trauma, as well as optometry.
 

The industry believes that in the short term, although the ophthalmology market has fluctuated due to the impact of the pandemic, its growth resilience remains strong. In the future, driven by trends such as the popularization of electronic products and an aging population, China's ophthalmology market will continue to grow, and the industry’s development space will become increasingly broad. At the same time, relevant companies’ enthusiasm for research and development is expected to remain high, and their performance may also see a new wave of growth.
 

Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.